SIRT1 Histone Deacetylase Expression Is Associated with Microsatellite Instability and CpG Island Methylator Phenotype in Colorectal Cancer

The class III histone deacetylase SIRT1 (sir2) is important in epigenetic gene silencing. Inhibition of SIRT1 reactivates silenced genes, suggesting a possible therapeutic approach of targeted reversal of aberrantly silenced genes. In addition, SIRT1 may be involved in the well-known link between obesity, cellular energy balance and cancer. However, a comprehensive study of SIRT1 using human cancer tissue with clinical outcome data is currently lacking, and its prognostic significance is uncertain. Using the database of 485 colorectal cancers in two independent prospective cohort studies, we detected SIRT1 overexpression in 180 (37%) tumors by immunohistochemistry. We examined its relationship to the CpG island methylator phenotype (CIMP), related molecular events, clinical features including body mass index, and patient survival. We quantified DNA methylation in eight CIMP-specific promoters (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) and eight other CpG islands (CHFR, HIC1, IGFBP3, MGMT, MINT1, MINT31, p14, and WRN) by MethyLight. SIRT1 overexpression was associated with CIMP-high (≥6 of 8 methylated CIMP-specific promoters, P=0.002) and microsatellite instability (MSI)-high phenotype (P<0.0001). In both univariate and multivariate analyses, SIRT1 overexpression was significantly associated with the CIMP-high MSI-high phenotype (multivariate odds ratio, 3.20; 95% confidence interval, 1.35–7.59; P=0.008). In addition, mucinous component (P=0.01), high tumor grade (P=0.02), and fatty acid synthase overexpression (P=0.04) were significantly associated with SIRT positivity in multivariate analysis. SIRT1 was not significantly related with age, sex, tumor location, stage, signet ring cells, cyclooxygenase-2 (COX-2), LINE-1 hypomethylation, KRAS, BRAF, BMI, PIK3CA, HDAC, p53, β-catenin, COX-2, or patient prognosis. In conclusion, SIRT1 expression is associated with CIMP-high MSI-high colon cancer, suggesting involvement of SIRT1 in gene silencing in this unique tumor subtype.

[1]  M. Loda,et al.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. , 2005, The Journal of molecular diagnostics : JMD.

[2]  L. Guarente,et al.  Genetic pathways that regulate ageing in model organisms , 2000, Nature.

[3]  J. Jass,et al.  Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer , 2007, Modern Pathology.

[4]  L. Guarente,et al.  Calorie Restriction— the SIR2 Connection , 2005, Cell.

[5]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[6]  W. Hahn,et al.  The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth , 2008, PloS one.

[7]  Shuji Ogino,et al.  A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. , 2008, Journal of the National Cancer Institute.

[8]  S. Grasset.  Where are the nurses? , 1981, RNABC news.

[9]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[10]  M. Loda,et al.  Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component , 2006, Modern Pathology.

[11]  J. Meyerhardt,et al.  Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. , 2007, Neoplasia.

[12]  Graham A. Colditz,et al.  The Nurses' Health Study: lifestyle and health among women , 2005, Nature Reviews Cancer.

[13]  Yang Shi,et al.  Histone lysine demethylases: emerging roles in development, physiology and disease , 2007, Nature Reviews Genetics.

[14]  L. Guarente,et al.  Sir2 links chromatin silencing, metabolism, and aging. , 2000, Genes & development.

[15]  M. Salto‐Tellez,et al.  Function of the SIRT1 protein deacetylase in cancer. , 2007, Biotechnology journal.

[16]  M. Loda,et al.  Cohort study of fatty acid synthase expression and patient survival in colon cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Hamilton,et al.  Targeted therapy of cancer: new roles for pathologists in colorectal cancer , 2008, Modern Pathology.

[18]  M. Loda,et al.  CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. , 2006, The Journal of molecular diagnostics : JMD.

[19]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[20]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[21]  Seonwoo Kim,et al.  Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma , 2008, Modern Pathology.

[22]  David Sinclair,et al.  Sirtuins in mammals: insights into their biological function. , 2007, The Biochemical journal.

[23]  M. Loda,et al.  Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP , 2007, Modern Pathology.

[24]  J. Mariadason.  HDACs and HDAC inhibitors in colon cancer , 2008, Epigenetics.

[25]  Robert Brown,et al.  CpG island methylator phenotype (CIMP) in cancer: causes and implications. , 2008, Cancer letters.

[26]  I. Forgacs.  GASTROENTEROLOGY , 1988, The Lancet.

[27]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[28]  B. Leggett,et al.  Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. , 2002, Cancer research.

[29]  M. Toyota,et al.  CIMP, at last. , 2005, Gastroenterology.

[30]  J. Issa,et al.  Targeting Aberrant Chromatin Structure in Colorectal Carcinomas , 2007, Cancer journal.

[31]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[32]  R. Wolff,et al.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. , 2005, Gastroenterology.

[33]  Kelly M. McGarvey,et al.  Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation , 2006, PLoS genetics.

[34]  Delin Chen,et al.  Mammalian SIRT1 Represses Forkhead Transcription Factors , 2004, Cell.

[35]  A. Kimura,et al.  Chromosomal gradient of histone acetylation established by Sas2p and Sir2p functions as a shield against gene silencing , 2002, Nature Genetics.

[36]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[37]  J. Herman,et al.  Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. , 2008, Carcinogenesis.

[38]  H. Sugimura,et al.  Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis , 2009, Modern Pathology.

[39]  S. Nemoto,et al.  Nutrient Availability Regulates SIRT1 Through a Forkhead-Dependent Pathway , 2004, Science.

[40]  Myriam Gorospe,et al.  Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase , 2004, Science.

[41]  L. Terracciano,et al.  Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status , 2008, Modern Pathology.

[42]  M. Loda,et al.  Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. , 2007, The Journal of molecular diagnostics : JMD.

[43]  S. Baylin,et al.  Tumor Suppressor HIC1 Directly Regulates SIRT1 to Modulate p53-Dependent DNA-Damage Responses , 2005, Cell.

[44]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[45]  Shuji Ogino,et al.  Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. , 2006, The Journal of molecular diagnostics : JMD.

[46]  S. Ogino,et al.  LINE‐1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer , 2008, International journal of cancer.

[47]  Hong Yang,et al.  Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer , 2007, Modern Pathology.

[48]  J. Issa,et al.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.

[49]  L. Guarente,et al.  Genetic links between diet and lifespan: shared mechanisms from yeast to humans , 2007, Nature Reviews Genetics.

[50]  J. Rine,et al.  The Flavoring Agent Dihydrocoumarin Reverses Epigenetic Silencing and Inhibits Sirtuin Deacetylases , 2005, PLoS genetics.

[51]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[52]  W. Grady.  CIMP and colon cancer gets more complicated , 2007, Gut.

[53]  Michael Grunstein,et al.  Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin , 2002, Nature Genetics.

[54]  John Quackenbush,et al.  Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample , 2008, PloS one.

[55]  L. Guarente,et al.  Negative control of p53 by Sir2alpha promotes cell survival under stress. , 2001, Cell.

[56]  S. Ogino,et al.  Molecular classification and correlates in colorectal cancer. , 2008, The Journal of molecular diagnostics : JMD.

[57]  G. Sauter,et al.  L1 is associated with micrometastatic spread and poor outcome in colorectal cancer , 2007, Modern Pathology.

[58]  S. Minucci,et al.  Human SIR2 deacetylates p53 and antagonizes PML/p53‐induced cellular senescence , 2002, The EMBO journal.

[59]  S. Ogino,et al.  PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. , 2008, Neoplasia.

[60]  L. Aaltonen,et al.  A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition , 2006, Nature Genetics.

[61]  E CARBONETTO,et al.  [Colon Cancer]. , 1958, El Dia medico.

[62]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.